Archive for May 2017

Foods For Brain Health

1. Eggs

Egg yolks contain choline. Studies are showing how deficiencies in choline may contribute to age related mental decline.
Weekly Recommendation: 4-5 times

2. Leafy Greens
Our mothers were so right to make us eat vegetables, since leafy greens are rich in folic acid which is essential for the metabolism of the long chain fatty acids in your brain.
Weekly Recommendation: Daily

3. Lean Beef
Lean beef is one of the best brain foods because is rich in vitamin B12, iron and zinc. These vitamins and minerals have been shown to maintain a healthy neural tissue. Iron deficiency may affect mental performance.
Weekly Recommendation: 3 times

4. Berries Including Blueberries, Strawberries or Blackberries
Studies show that people who eat strawberries improve their memory and their motor skills. In addition, their critical antioxidant properties can protect your brain from the oxidative process.
Weekly Recommendation: Daily

5. Dark Chocolate
Who doesn’t like a nice piece of dark chocolate? I do. Dark chocolate does not only taste good but it is also an excellent nutrient for the brain. Dark chocolate is one of the best natural stimulant offering incredible concentration powers and very powerful antioxidant properties containing natural stimulants that increase the production of feel-good endorphins. Trick: You need to find dark chocolate with less than 10 grams of sugar per serving for optimal benefits.
Weekly Recommendation: 4 pieces, 4 times a week

6. Salmon
Salmon contains omega-3 fatty acids, which studies have shown to be essential for brain function.
Weekly Recommendation: 3 times

7. Ground Cinnamon and Dried Oregano
Certain spices have powerful antioxidant properties.
Weekly Recommendation: Daily

8. Walnuts
“A snack that looks like a brain it can’t be bad for your brain” Walnuts are rich in protein and contain omega-3 fatty acids and vitamins E and B6, which all promote healthy neural tissue.
Weekly Recommendation: Daily

9. Whole Grains
Whole grains deliver fiber and vitamin E that help promote cardiovascular health, which helps improve the circulation to the brain.
Weekly Recommendation: Daily

10. Yogurt
Yogurt and other dairy foods are filled with protein and vitamin B that are essential to nerve cells and improve the communication between nerve cells
Weekly Recommendation: Daily
Last and not least add plenty of water  since proper hydration helps your brain perform at a high levels.
Nutrients are not only for your body they are absolutely crucial for your brain. Life is about choices and selecting the right nutrients can play a key role in your health.

In a nutshell:   Brain Foods: Eggs, Leafy green vegetables, lean beef, blueberries, strawberries, blackberries, dark chocolate, salmon, ground cinnamon and dried oregano, walnuts, whole grains and yogurt. Add plenty of water since proper hydration help brain function. Avoid fried foods and include Omega 3 rich foods, essential for cognitive processing.
Food For Brain
Who wants to become smarter? Who wants to feel healthier? I do! Many recent studies show the importance of how certain nutrients can positively affect the brain, specifically in areas of the brain related to cognitive processing or feelings and emotions.

Healthy Foods To Sharpen Your Brain
In general terms, you want to follow a healthy diet for your brain that will lead to a healthy blood flow, improvement of mental sharpness and reduction of the risk of heart disease and neurodegenerative diseases such as Alzheimer’s.
According to Gomez Pinilla, a neurobiolgist “Exercise and select diets have important influences on health and plasticity of the nervous system”. According to his line of research – The key is to avoid fried foods and add more Omega 3 fatty acids like Salmon or walnuts and always remember when ingesting fish to watch the mercury level and keep it as low as possible.
According to Dr Pinilla’s study “New evidence indicates that exercise, in combination with dietary factors, exerts its effects by affecting molecular events related to the management of energy metabolism and synaptic plasticity”

Why are Omega 3 Fatty Acids So Important for our Brain?
According to one study, the super-fats your brain needs most are omega-3 fatty acids. Your brain converts them into DHA (docosahexaenoic acid) which enhances neuronal communication and promotes neuronal growth.

Food for thought: Food and nutrients represent energy to our bodies the same way that when we use our car we need to fill the gas tank. Unfortunately, we generally take better care of our cars than our bodies. Why is that? Science is telling us that consuming the right nutrients can help our health, aging process, and more efficient brain-body functioning.

New Four-Strain Influenza Vaccine, VaxigripTetra

New Four-Strain Influenza Vaccine, VaxigripTetra™, Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
New VaxigripTetra™ vaccine:
• A 4-strain influenza vaccine for people 36 months of age and older,
• Helps protect children, adults and seniors against both influenza B strains (B/Victoria and B/Yamagata),
• Newest addition to the Vaxigrip® family of influenza vaccines.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that its quadrivalent influenza vaccine VaxigripTetra™ obtained a positive end of procedure from the German Reference Member State Paul Ehrlich Institute, as a conclusion of the European Decentralized Procedure. Marketing Authorizations can now be issued in the Reference Member State (Germany) and each of the Concerned Member States involved in this procedure. VaxigripTetra™ is a four-strain influenza vaccine, containing two A strains (A/H1N1 and A/H3N2) and two B strains (B/Victoria and B/Yamagata), for use in individuals aged 36 months or older. VaxigripTetra™ is the newest addition to the Vaxigrip® family of influenza vaccines.
Currently, the majority of seasonal influenza vaccines are trivalent meaning that they protect against three strains: two A strains and a single B strain (B/Victoria or B/Yamagata). However, two distinct influenza B strains (B/Victoria and B/Yamagata) now co-circulate worldwide in varying and unpredictable proportions[1]. In recent years, influenza B viruses represented around 23% of the circulating strains around the world. These proportions can be as high as 90% during some seasons and are therefore an important cause of influenza disease[2]. Given this current virological situation with the co-circulation of the two B strains, influenza vaccines need to be adapted and to fit with the current virological situation to ensure broader level of protection. Because trivalent influenza vaccines only contain one B strain, this co-circulation makes the selection of the right strains to be included in the seasonal vaccine very difficult to predict. As an example in Europe in 2015 92%[3] of the documented B influenza cases were caused by the B/Victoria strain not included in the vaccine. Adding the second B strain to VaxigripTetra™ will address the unpredictability issue.
“For over 60 years the expertise of Sanofi Pasteur has been committed to providing new immunization solutions for the prevention of influenza to better protect lives and help healthcare providers meet the specific immunization needs of all types of their patients. This new quadrivalent influenza vaccine, which includes both co-circulating B strains, completes our long line of Vaxigrip® family vaccines dedicated to fighting influenza infections and its complications. Once launched in Europe VaxigripTetra™ will offer broader protection for people from 36 months and older and support our public health ambition to constantly innovate to save lives worldwide” said David Loew, Executive Vice President Sanofi Pasteur.
The World Health Organization includes quadrivalent influenza vaccines in its recommendations, stating “Quadrivalent influenza vaccines that could potentially provide wider protection against influenza B viruses are becoming available and recommendations should not be limited to trivalent vaccine.” [4]
From a public health perspective, using quadrivalent rather than trivalent influenza vaccines could have resulted in a further reduction of up to 1.6 million influenza cases, 37,300 influenza-related hospitalizations and 14,800 influenza-related deaths in the EU over a decade[5].
Sanofi Pasteur supports influenza immunization policies and is committed to developing vaccine solutions that fit with the influenza epidemiology. VaxigripTetra™ is the newest formulation designed by Sanofi Pasteur, offering a quadrivalent influenza vaccine. VaxigripTetra™ includes two A strains and two B strains to help provide broader protection for all age groups as of 36 months. Sanofi Pasteur intends to progressively switch all its trivalent influenza vaccines to quadrivalent influenza vaccines worldwide.
About the evolution of influenza vaccines
Influenza viruses mutate often and the antigenic and ecological evolution results in the need to adapt the vaccine composition annually to ensure it remains effective[6]. Each winter the strains for the seasonal influenza vaccines are selected from the influenza strains anticipated to circulate in the Northern Hemisphere during the approaching influenza season by WHO. Until 1978, seasonal influenza vaccines contained only two strains (one strain of type A influenza and one strain of type B influenza), when the decision was made to incorporate a second type A influenza strain to help provide protection against both A strains that were co-circulating[7]. Since then, influenza vaccines have been trivalent to help protect against three strains of influenza virus: a type A(H1N1), a type A(H3N2) and one type B.
However, since the 2001-2002 season, influenza B viruses have diverged into two antigenically distinct lineages (the Victoria and Yamagata lineages). Both B lineages have co-circulated with varying prevalence by season and region, supporting the need for extended protection with quadrivalent influenza vaccines[8].
About influenza and vaccination
Influenza is a serious respiratory illness[9]. Each year, 3 million to 5 million cases of severe illness are reported worldwide. Depending on virus virulence during the influenza season, influenza associated-deaths can range from 250,000 to 500,000 people[10]  worldwide.
In Europe, in the absence of vaccination, the annual burden related to influenza was estimated at 22 million cases, 3.5 million flu-associated hospitalizations and 171,000 flu-associated deaths[11]. Currently seasonal influenza vaccination prevents on average between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths every year[12]. The World Health Organization recommends vaccination to help prevent influenza for everyone six months of age and older.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company’s heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: or
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.